{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:44Z","timestamp":1791414104616,"version":"4.3.3"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"MicuRx"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,10,20]]},"abstract":"<jats:p>\n            Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (\n            <jats:italic>n<\/jats:italic>\n            \u2009=\u20091,211). Contezolid demonstrated potent activity against\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/1\u2009mg\/liter), coagulase-negative\n            <jats:italic>Staphylococcus<\/jats:italic>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.25\/0.5\u2009mg\/liter),\n            <jats:italic>Enterococcus<\/jats:italic>\n            spp.\n          <\/jats:p>","DOI":"10.1128\/aac.01195-20","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T13:20:57Z","timestamp":1597065657000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["<i>In Vitro<\/i>\n            Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe"],"prefix":"10.1128","volume":"64","author":[{"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"MicuRx Pharmaceuticals, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz074"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00101-13"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz559"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.006"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.6.1234"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01526-13"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1750595"},{"key":"e_1_3_2_12_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed. CLSI document M07","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed. CLSI document M07. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","volume-title":"Performance standards for antimcirobial susceptibility testing; 30th informational supplement. CLSI document M100","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimcirobial susceptibility testing; 30th informational supplement. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","unstructured":"EUCAST. 2020. Breakpoint tables for interpretation of MICs and zone diameters version 10.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf. Accessed January 2020."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12144"},{"key":"e_1_3_2_16_2","unstructured":"Pfizer Inc. 2020. Zyvox (linezolid) prescribing information. Pfizer Inc. New York NY. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=649."},{"key":"e_1_3_2_17_2","unstructured":"Cubist Pharmaceuticals. 2014. Sivextro (tedizolid phosphate) package insert. Cubist Pharmaceuticals Lexington MA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00041"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06964-1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm401931e"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2019.1609740"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky099"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00175-20"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv302"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.008"},{"key":"e_1_3_2_26_2","unstructured":"MicuRx Pharmaceuticals Inc. 2019. MicuRx pharmaceuticals reports positive top-line results from a US phase 2 ABSSSSI clinical trial of novel antibiotic contezolid acefosamil. https:\/\/www.businesswire.com\/news\/home\/20190909005015\/en\/MicuRx-Pharmaceuticals-Reports-Positive-Top-Line-Results-Phase."},{"key":"e_1_3_2_27_2","unstructured":"MicuRx Pharmaceuticals Inc. 2019. MicuRx announces positive top-line results from phase 3 trial of contezolid (MRX-I) in adults with complicated skin and soft tissue infection. https:\/\/www.trialsitenews.com\/micurx-announces-positive-topline-results-from-phase-3-trial-of-contezolid-mrx-i-in-adults-with-complicated-skin-and-soft-tissue-infection-2\/."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01195-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01195-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:36:09Z","timestamp":1645479369000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01195-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10,20]]}},"alternative-id":["10.1128\/AAC.01195-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01195-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"2020-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01195-20"}}